Analysts See $-0.45 EPS for TG Therapeutics, Inc. (TGTX); Agf Investments America Boosted Its Trimble (TRMB) Position

Trimble Inc. (NASDAQ:TRMB) Logo

Analysts expect TG Therapeutics, Inc. (NASDAQ:TGTX) to report $-0.45 EPS on March, 14.They anticipate $0.01 EPS change or 2.17% from last quarter’s $-0.46 EPS. After having $-0.43 EPS previously, TG Therapeutics, Inc.’s analysts see 4.65% EPS growth. The stock increased 0.22% or $0.01 during the last trading session, reaching $4.53. About 1.55 million shares traded or 21.97% up from the average. TG Therapeutics, Inc. (NASDAQ:TGTX) has declined 37.94% since February 12, 2018 and is downtrending. It has underperformed by 37.94% the S&P500. Some Historical TGTX News: 24/04/2018 – TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting; 08/03/2018 – TG Therapeutics 4Q Loss/Shr 46c; 18/04/2018 – TG Therapeutics: Clinical Trials Will Be Focused on Potential Synergism Between TG-1601 and Other Drugs in TG Pipeline; 21/05/2018 – TG Therapeutics Presenting at Conference Jun 4; 17/05/2018 – TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association; 15/03/2018 – TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting; 24/04/2018 – TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multip; 27/03/2018 – TG Therapeutics Presenting at Conference Tomorrow; 08/05/2018 – TG Therapeutics 1Q Loss/Shr 59c; 15/03/2018 – TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annua

Agf Investments America Inc increased Trimble Inc. (TRMB) stake by 11.87% reported in 2018Q3 SEC filing. Agf Investments America Inc acquired 23,402 shares as Trimble Inc. (TRMB)’s stock declined 16.24%. The Agf Investments America Inc holds 220,524 shares with $9.58M value, up from 197,122 last quarter. Trimble Inc. now has $9.79 billion valuation. The stock increased 0.96% or $0.37 during the last trading session, reaching $38.98. About 1.01M shares traded. Trimble Inc. (NASDAQ:TRMB) has declined 12.77% since February 12, 2018 and is downtrending. It has underperformed by 12.77% the S&P500. Some Historical TRMB News: 07/05/2018 – TRIMBLE SEES 2Q ADJ EPS 42C TO 46C, EST. 45C; 13/03/2018 – Trimble Announces Call for Speakers for its 2018 Dimensions International User Conference; 24/04/2018 – TRIMBLE’S OUTLOOK REMAINS STABLE BY MOODY’S; 23/04/2018 – TRIMBLE: VIEWPOINT TO CONTRIBUTE $200M OF NON-GAAP REV. IN 2019; 23/04/2018 – Trimble Unveils Pan-India Program To Train Next Generation Construction Industry Professionals; 23/04/2018 – Trimble Expects Viewpoint to Contribute About $200M of Non-GAAP Rev in 2019; 20/04/2018 – Trimble Acquires the Assets of FabSuite to Expand its Steel Fabrication Software Portfolio; 18/04/2018 – Dreyfus Third Century Adds Abbott, Exits Trimble; 19/04/2018 – Trimble Adds New Distributor to its Global Vantage Network for Agriculture in Hungary; 31/05/2018 – HarvestMark and iFood Partner to Offer a Comprehensive Food Safety, Traceability and Quality Management Platform

More notable recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: Nasdaq.com which released: “Has TG Therapeutics (TGTX) Outpaced Other Medical Stocks This Year? – Nasdaq” on January 28, 2019, also Nasdaq.com with their article: “Health Care Sector Update for 01/22/2019: TGTX, SRNE, JNJ, ABT, MRK, AMGN, PFE – Nasdaq” published on January 22, 2019, Seekingalpha.com published: “TG Therapeutics up 7% premarket on positive TG-1101/TGR-1202 data – Seeking Alpha” on January 30, 2019. More interesting news about TG Therapeutics, Inc. (NASDAQ:TGTX) were released by: Nasdaq.com and their article: “Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings? – Nasdaq” published on February 11, 2019 as well as Seekingalpha.com‘s news article titled: “APHA, EBAY among premarket gainers – Seeking Alpha” with publication date: January 22, 2019.

Investors sentiment decreased to 1.1 in 2018 Q3. Its down 0.37, from 1.47 in 2018Q2. It dived, as 23 investors sold TG Therapeutics, Inc. shares while 27 reduced holdings. 22 funds opened positions while 33 raised stakes. 45.96 million shares or 15.90% more from 39.66 million shares in 2018Q2 were reported. Millennium Mngmt Limited Co owns 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 281,315 shares. Schwab Charles Investment Mngmt Inc owns 329,647 shares. 15,022 were accumulated by Sg Americas Secs Limited. Missouri-based Cutter & Brokerage has invested 0.07% in TG Therapeutics, Inc. (NASDAQ:TGTX). Janney Capital Mgmt Limited Liability holds 15,995 shares or 0% of its portfolio. Gam Holdings Ag has 0.02% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 98,600 shares. 683 Mgmt Ltd Liability Co holds 0.18% or 500,000 shares in its portfolio. Art Advsrs Lc holds 0.01% or 26,819 shares. Hanson Mcclain Inc stated it has 62 shares. Fmr, Massachusetts-based fund reported 2.94 million shares. Fifth Third Comml Bank holds 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX) for 6,600 shares. Moreover, Citadel Advsrs Limited Liability Co has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). Stratos Wealth Prtn Limited has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Metropolitan Life Ins holds 0% or 4,374 shares. 4,125 are held by Hsbc Hldg Public Ltd Co.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $348.03 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

Since August 14, 2018, it had 0 insider buys, and 8 sales for $2.55 million activity. 1,833 shares were sold by MATTHEWS DARRYL R, worth $77,877. The insider PAINTER ROBERT G sold $29,333. The insider KIRKLAND JAMES A sold 8,530 shares worth $345,849. SANKPAL SACHIN also sold $135,556 worth of Trimble Inc. (NASDAQ:TRMB) on Wednesday, September 12. On Monday, August 27 Janow Merit E sold $1.24M worth of Trimble Inc. (NASDAQ:TRMB) or 30,000 shares.

Agf Investments America Inc decreased Unum Group (NYSE:UNM) stake by 21,145 shares to 24,617 valued at $962,000 in 2018Q3. It also reduced Moody’s Corp. (NYSE:MCO) stake by 2,039 shares and now owns 33,773 shares. On Semiconductor Corp. (ONNN) was reduced too.

More notable recent Trimble Inc. (NASDAQ:TRMB) news were published by: Benzinga.com which released: “Trimble Navigation Limited (NASDAQ:TRMB) – Infrastructure Business Segment Leads Trimble Revenue – Benzinga” on February 11, 2019, also Nasdaq.com with their article: “Trimble (TRMB) Q4 Earnings Beat Estimates, Revenues Up Y/Y – Nasdaq” published on February 07, 2019, Nasdaq.com published: “IJK, UGI, TRMB, PTC: Large Outflows Detected at ETF – Nasdaq” on February 08, 2019. More interesting news about Trimble Inc. (NASDAQ:TRMB) were released by: Nasdaq.com and their article: “Interesting TRMB Put And Call Options For March 15th – Nasdaq” published on January 23, 2019 as well as Nasdaq.com‘s news article titled: “Trimble Navigation (TRMB) Reports Next Week: Wall Street Expects Earnings Growth – Nasdaq” with publication date: January 30, 2019.

Among 2 analysts covering Trimble (NASDAQ:TRMB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Trimble had 2 analyst reports since November 2, 2018 according to SRatingsIntel. The rating was maintained by Robert W. Baird on Friday, November 2 with “Outperform”. The stock of Trimble Inc. (NASDAQ:TRMB) earned “Overweight” rating by JP Morgan on Thursday, January 10.

Trimble Inc. (NASDAQ:TRMB) Institutional Positions Chart